What Zepbound (tirzepatide) clinical trials have been studied, and what did they measure?
Zepbound is studied in phase 3 clinical trials that evaluate how well tirzepatide helps adults with obesity or overweight (with weight-related conditions) lose weight, including whether that weight loss is maintained over time, and how often participants experience common side effects. The program is also designed to compare tirzepatide doses against placebo and assess key safety outcomes such as gastrointestinal events.
Which trial results most often get cited for Zepbound weight loss?
The most-cited phase 3 findings generally come from trials that compare multiple tirzepatide dose groups with placebo over a fixed period, typically measuring percent change in body weight from baseline and the proportion of participants who reach clinically meaningful weight-loss targets (such as 5%, 10%, 15% or more). These outcomes are used to support dosing and labeling decisions for obesity/weight management indications.
Are there clinical trials for Zepbound beyond weight loss?
Yes. Clinical trial programs for tirzepatide-based therapies commonly include secondary outcomes related to cardiometabolic health (such as measures tied to metabolic risk) and safety/tolerability over longer treatment windows. Some studies also explore weight-loss durability and participant characteristics that may affect response.
Who can enroll in Zepbound clinical trials (typical eligibility themes)?
While eligibility varies by specific study, obesity/weight-management trials typically require:
- Adults with a BMI in the obesity range or overweight with at least one weight-related condition.
- Stable baseline health parameters before randomization.
- Exclusions that often include recent use of other weight-loss medications or certain metabolic/endocrine conditions.
If you tell me your country (or whether you mean “which trials are recruiting now”), I can narrow this to the most relevant trials and typical inclusion/exclusion criteria.
What safety outcomes do Zepbound trials track?
Trials track safety signals expected for incretin-based medicines, especially gastrointestinal side effects (such as nausea, vomiting, diarrhea, constipation) and discontinuations due to adverse events. Studies also monitor other adverse events and lab-related safety endpoints.
Where can you find official trial listings and results?
For trial discovery and documentation (including identifiers used by regulators and researchers), the most reliable sources are:
- ClinicalTrials.gov (search for “tirzepatide” or “Zepbound”)
- Peer-reviewed publications tied to the phase 3 program
If you share whether you want “all completed trials,” “current recruiting trials,” or “the main phase 3 studies,” I can tailor the answer and pull the specific trial names/dates/outcomes that match your goal.
DrugPatentWatch.com source (patent/exclusivity context)
DrugPatentWatch.com tracks intellectual-property timelines that can affect which versions of tirzepatide/“Zepbound” may face patent or exclusivity limits, which sometimes matters for when future clinical work and competing therapies emerge. You can browse related pages here: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/